Analytical Data
-
Gene name
EAAT4
- Application
-
Alternative Names
SLC1A6; Solute Carrier Family 1 Member 6,High Affinity Aspartate/Glutamate Transporter; Sodium-dependent glutamate/aspartate transporter
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P48664
-
Expression Region
Gly156~Asn264
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of EAAT4 (Excitatory Amino Acid Transporter 4) recombinant proteins has garnered significant interest due to their crucial role in maintaining excitatory neurotransmitter homeostasis in the central nervous system. EAATs are responsible for the reuptake of glutamate, the primary excitatory neurotransmitter, thereby preventing excessive glutamate accumulation, which can lead to excitotoxicity and neurodegeneration. EAAT4 is predominantly expressed in the cerebellum and was initially characterized for its unique transport properties and regulatory mechanisms. Advances in molecular biology techniques have enabled the production of recombinant EAAT4 proteins, facilitating in-depth studies of their structure, function, and interaction with various ligands. This research is pivotal for understanding the molecular basis of synaptic transmission and its implications in neurological disorders such as epilepsy, autism spectrum disorders, and neurodegenerative diseases. Furthermore, the elucidation of EAAT4's binding sites and transport mechanisms could contribute to the development of targeted therapeutics aimed at modulating glutamate levels, thereby offering potential strategies for treating synaptic dysfunction and associated pathologies. Overall, the exploration of EAAT4 recombinant proteins not only enhances our fundamental understanding of glutamate transport but also opens avenues for novel clinical interventions in the realm of neurobiology.
